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Osteonecrosis of the Jaw (ONJ) is an adverse event reported especially in patients receiving cancer
treatments regimen, bisphosphonates (BPs), and denosumab. We performed an open-label, prospective
study in patients treated with zoledronic acid who developed ONJ lesions 42.5 cm, and had no beneﬁt
after the treatment with the standard therapy, to evaluate the efﬁcacy and tolerability of medical ozone
(O3) treatment delivered as gas insufﬂations on each ONJ lesions.
Twenty-four patients (mean age 62.5, range 41–80; 12 female) with bone metastases due to breast (11),
prostate (4)and lung (4)cancers, myeloma (2), or osteoporosis (3), previously treated with zoledronic acid
and not underwent dental preventive measures and with ONJ lesions 42.5 cm, were observed and treated
with topical O3 gas insufﬂation every third day for a minimum of 10 for each pathological area or till necrotic
bone sequestrum or surgery. We used a special insufﬂation bell-shaped device adjusted to the speciﬁc
characteristics of the patient, capable of eliminating any residue of O3 diffusion by degrading it and releasing
O2 into the air. Azithromicin 500 mg/day was administered for 10 days in all patients before the ﬁrst three
gas insufﬂation although they had previously received various cycles of antibiotics. Ten patients required
more than 10 O3 gas insufﬂations due to multiple lesions and/or purulent sovrainfections; one patient
received two further O3 insufﬂations while waiting the day of surgery. Six of 24 patients interrupted the O3
gas therapy for oncological disease progression (ﬁve patients) and for fear of an experimental therapy (one
patient). Six patients had the sequestrum and complete or partial (one patient) spontaneous expulsion of the
necrotic bone followed by oral mucosa re-epithelization after a range of 4–27 of O3 gas insufﬂations. No
patient reported adverse events. In 12 patients with the largest and deeper ONJ lesions, O3 gas therapy
produced the sequestrum of the necrotic bone after 10 to 38 insufﬂations; surgery was necessary to remove
it (11 patients). Of interest, removal was possible without the resection of healthy mandible edge because of
the presence of bone sequestrum.
All together the response rate was 75.0% (95% CI, 53.3–90.2%) in ITT analysis and 100% (95% CI,
81.5–100%) in the PP analysis.
In all patients treated with O3 gas 7 surgery, no ONJ relapse appeared (follow-up mean 18 months,
range 1–3 years). Medical O3 gas insufﬂations is an effective and safe treatment for patients treated
with BPs who developed ONJ lesions 42.5 cm.
Short abstract: ONJ is an adverse event reported in patients receiving cancer treatments regimen,
bisphosphonates and denosumab. We performed an open-label, prospective study in 24 patients with
solid tumours, myeloma or osteoporosis due to hormonal therapy, treated with zoledronic acid without
previuos preventive dental screening, who developed ONJ lesions 42.5 cm, and had no beneﬁt after
standard therapy, to evaluate the efﬁcacy and tolerability of medical ozone (O3) treatment delivered as
gas insufﬂations on each ONJ lesions.
The patients were treated with O3 every third day for a minimum of 10 for each pathological area or
till necrotic bone sequestrum or surgery. Eleven patients required more than ten O3 gas insufﬂations.. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ewed and approved by the Ethics Committee of National Cancer Institute of Milan and are in accordance with the
amended in 1975, 1983, 1989, 1996 and 2000) of the World Medical Association.
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C.I. Ripamonti et al. / Journal of Bone Oncology 1 (2012) 81–8782Six of 24 patients interrupted the therapy for oncological disease progression. Six patients had the
sequestrum and complete or partial (one patient) spontaneous expulsion of the necrotic bone followed
by oral mucosa re-epithelization after a range of 4 to 27 of O3 gas insufﬂations. No patient reported
adverse events. In 12 patients with the largest and deeper ONJ lesions, O3 gas therapy produced the
sequestrum of the necrotic bone after 10 to 38 insufﬂations; surgery was necessary to remove it (11
patients). Of interest, removal was possible without the resection of healthy mandible edge because of
the presence of bone sequestrum.
All together the response rate was 75.0% (95% CI, 53.3–90.2%) in ITT analysis and 100% (95% CI,
81.5–100%) in the PP analysis.
In all patients treated with O3 gas 7 surgery, no ONJ relapse appeared (follow-up mean 18 months,
range 1–3 years).
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteonecrosis of the jaw (ONJ) is an adverse event reported in
patients receiving BPs and RANKL inhibitors such as denosumab
[1–9].
ONJ is deﬁned as the persistence of exposed bone in the oral
cavity, despite an adequate treatment for six weeks, without local
evidence of malignancy and no prior radiotherapy to the affected
region [10]. However, ONJ may present with the non-exposed
variant of ONJ.
The pooled risk estimated incidence of ONJ, in BPs users, is 2,4%
[11–14]. In RCTs comparing zoledronic acid and denosumab in 5677
patients who underwent screening dental procedure, 89 ONJ cases
were reported of which 52 in the denosumab group [8,11–13].
Factors adversely inﬂuencing bone remodelling are considered to
be pivotal in the pathophysiology of the ONJ and preclinical data
shows that the bone turnover is higher in the jaws with respect to
other skeletal areas [10,15–17]. The presence of chronic periodontal
pathologies, the duration and type of BP therapy, tooth extractions,
the use of dental appliances, denture traumatisms, invasive dental
surgery during the course of BP therapy, poor oral hygiene, con-
current disease (e.g. diabetes, peripheral vasculopathy) and the
concomitant use of chemotherapy, antiretroviral therapies, thalido-
mide, and corticosteroids or the presence of anaemia are considered
putative additional risk factors [1–5,18,19]. In a retrospective analy-
sis of 567 cases Vescovi et al. [20] studied the differences between
the non surgery-triggered vs surgery-triggered variants
bisphosphonate-related osteonecrosis of the jaws. In 205 cases
(36.2%) of ONJ no surgery was performed as against 362 cases
(63.8%) of post-local invasive procedure forms including tooth
extraction in 361 cases and implant placement in one case only.
Bisphosphonates are a well-established, standard-of care treat-
ment option to reduce the frequency and severity and time of onset
of the skeletal related events (SREs) in patients with bone metas-
tases due to either solid tumours or multiple myeloma [21–33].
From many years, BPs have been incorporated into clinical practice
recommendations for these patients [33–39]and denosumab has
been approved in many countries for the delay of onset of SREs due
to bone metastasis in breast or prostatic cancer patients.
Preventive dental measures, after dental screening examina-
tion [1,40–44], are advocated to reduce the ONJ incidence
[14,45,46]due to their efﬁcacy in patients with bone metastases
but not in oncological patients with osteoporosis yet. Recent
recommendations for ONJ, include a conservative approach with
intermittent prophylactic antibiotic therapy, rinses with oral
chlorhexidine and debridement [44]; moreover a careful seques-
trum removal is recommended [1,17,40–47].
In a previous study [47]we evaluated the efﬁcacy and toler-
ability of localised topical application of an oil suspension enriched
with medical O3 gas, as treatment for ONJ lesions r2.5 cm in
another sample of patients who failed to respond to various cyclesof antibiotics. Unexpectedly, total sequestration of the necrotic
bone, with spontaneous expulsion in eight patients and new bone
formation around the necrotic area in two patients was observed.
No patient required surgical intervention. In two patients with pre-
and post-treatment X-rays, no residual bone lesions were observed
after treatment.
Ozone is a gas naturally produced by atmospheric air; medical
ozone is produced from oxygen. Its role in treating bone lesions has
been previously reported [47]. Ozone has antimicrobical and
wound-healing properties. The role of O3 produced by air to treat
ONJ has been evaluated in some pre-clinical and clinical studies
because it was thought that O3 could induce the repair of tissues by
cleansing the osteonecrotic lesions, which leads to mucosal healing
[47–53]. Ozone therapy has previously shown to enhance the
beneﬁts of surgical and pharmacologic treatments of ONJ when
administered before and after treatment procedures [47,51,53].
The aim of this open-label, prospective study, was to investi-
gate the efﬁcacy and tolerability of medical O3 gas (produced
from pure oxygen and not from air) topical insufﬂations, as the
treatment for ONJ lesions 42.5 cm in patients treated with BPs
whose ONJ lesion did not heal with prior conservative therapy or
relapsed after surgery performed before the patients arrived to
our hospital for the speciﬁc consultation and cure with the Dental
Team and the Supportive Care in Cancer Team.
2. Patients and methods
2.1. Eligibility criteria
All adult patients with solid tumours and multiple myeloma on
stable disease or patients with osteoporosis due to hormonal
therapy, who previously received nitrogen-containing BP treatment
in the absence of preventive screening carried out by a dentist and a
dental care team and who developed stage two ONJ lesions [10,44],
and had no beneﬁt after the treatment with the standard therapy,
were included in the study. The patients with lesions 42.5 cm
were considered for O3 gas therapy after they gave the consensus.
No patient took part in the previous published study [47]. No
patient with metastatic disease of the jaw or osteoradionecrosis
or treated with radiotherapy to the jaws were included.
2.2. Efﬁcacy criteria
The level of clinical response was: (1) bone sequestrum followed
by spontaneous expulsion of the necrotic bone with re-epithelization
of oral mucosa and with regenerated epithelial tissue or (2) bone
sequestrum followed by surgery to remove necrotic bone.
2.3. Safety criteria
The treatment area was assessed for the presence or absence
of oral mucosa redness around the lesion area, pain, progressive
Fig. 1. Bell used during insufﬂation on the ONJ lesion to avoid O3 gas diffusion.
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or bleeding. Moreover odour intolerance, burning mucosa, cough-
ing due to local irritation of respiratory tract, dysphagia post
treatment, symptoms related to skin sore or mucosal lesion was
assessed.
2.3.1. Procedure of O3 gas insufﬂation
All the procedures are performed by two experienced dentists
of the Dental Care Team (MM, EC).
Although antibiotic therapy had been received frequently by
the patients prior to study entry, all the patients were pre-treated
with azithromicin 500 mg/day for 10 days prior to the initiation of
the medical O3 gas treatment to reduce the local essudation/
infection caused by the exposition of necrotic bone, the dehis-
cence of the mucous membranes and the difﬁculty in maintaining
proper oral hygiene.
The choice of azithromicin was dictated by the fact that the
patients had previously been treated with various types of antibiotics
other than azithromicin. Moreover, clinical experience has shown
treatment with azitromicinale to be the best, fastest and most
durable remissions of local suppuration. To date, after several years
of treatment of patients with ONJ, we believe that the drug is more ‘in
the appropriate population of patients’ which came to our attention.
Table 1 shows the procedures for O3 insufﬂation after 10 days
of antibiotic treatment.
Before each treatment the condition of the mucosa and the
stability of the necrotic bone must be checked to evaluate
whether or not it needs to be removed.
Each patient was treated for with a minimum of 10 applica-
tions of O3 gas once every three days on each lesion area. When
patients showed necrotic bone sequestrum and spontaneous
expulsion with O3 gas applications were stopped after few
insufﬂations . In patients with plurifocal locations, with extensive
injury (and for which a insufﬂation bell Fig. 1 was packed and
used for each side application) or in the case of abundant purulent
secretions, a higher number of O3 gas applications were adminis-
tered because the concentrations of O3 initially interacted with
the bacteria and purulent or essudative secretions. Each O3 gas
insufﬂation lasted for 10 min.
When necrotic bone was not spontaneously expelled even if
the sequestrum was present, the patients were eligible for
surgical resection of the necrotic bone, rotation of the mucosa
lap, and surgical joining of the two edges.
2.3.2. Assessments
Efﬁcacy and safety evaluations were performed after each O3
gas application and during the follow-up period scheduled at one,
two, three, and four months after the completion of the treatmentTable 1
Procedures performed to administer O3 gas.
- The exposed bone and osteomucosal edge were cleaned with a tartar supersonic scal
gas through the mucosa around the ONJ lesion.
- An impression of the affected arch was taken using a perforated impression tray a
- Once the impression has been removed from the mouth, the marginal seal of the imp
a demographic pencil was used to make ONJ lesion reference points on the impressi
- Having identiﬁed the area corresponding to the lesion site, the ‘‘insufﬂations chamb
impression material to obtain a space in which the gas to be insufﬂate onto the trea
- We make calibrated holes in the perforated impression tray, at the proximal and dis
- Once in position, we checked the ﬁt of the ‘‘insufﬂations chamber’’, by checking th
- The tubes were then connected to the ozone dispensing device, along with the retu
chamber’s seal margin, thus making it possible to recover any ozone present after co
- Insufﬂations, were monitored constantly by the practitioner who can, when necessa
constant at 20 ppm þ/1.
- Flow control was made possible by constant monitoring of the ozone produced tha
time concentration control.
- At the end of the treatment, the insufﬂations chamber was removed from the mouth, tand then every six months. In particular at the end of all O3 gas
insufﬂation the damage of mucous tissues has been evaluated.
Moreover, pain intensity was assessed at each visit by means
of a self-reported numerical rating scale (NRS). The treatment was
stopped when patients showed clinical response (spontaneous
expulsion of necrotic bone or surgery to remove the sequestrum)
or undesirable adverse effects or when Performance Status
worsened due to disease progression.2.3.3. Study design and statistical considerations
This was a single-centre, open-label, Simon two-stage optimal
design study [54]. The primary efﬁcacy end point of the study was
the clinical response, as previously deﬁned. During stage one, an
enrolment of nine patients was required. If no response was
observed, then the study had to be terminated. If at least one
response was observed, the trial could continue to stage two and an
additional 15 patients enroled. After completion of the second stage
of the study, the treatment would be considered worthy of further
investigation if at least three responses were observed. The study
design yielded a 490% probability of a positive result if the true
response rate was 425%, and 490% probability of a negative result
if the true response rate was o5%. The study design incorporated
monitoring of treatment associated toxicity, with a Bayesian stop-
ping rule in case of a 90% posterior probability of a toxicity rate
greater than 10%. The response rate was computed as the percen-
tage of responding patients over the total number of patients
accrued. Calculation of the corresponding 95% conﬁdence interval
(95% CI) was based on the binomial distribution.er in order to reduce the infections at gum level and favour the penetration of O3
nd addition silicone impression material.
ression material on the healthy gum around the lesion was checked; if necessary
on material.
er’’ was prepared, creating a hollow in the impression by carefully removing the
tment area can circulate (Fig. 1).
tal margins of the lesion, for the tubes delivering the ozone gas to pass through.
e stability and seal on the marginal mucosa.
rn pipe that, using an aspiration pump, allows a perfect ﬁt on the mucosa at the
ntact that is not transformed into oxygen inside the chamber.
ry, use a ﬂow-metre to adjust the amount of ozone applied, which must be kept
nks to the presence in the device of a mass spectrophotometer that allows real-
hen washed and disinfected by emersion in sterilising product for subsequent use.
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The patients’ demographics, baseline disease characteristics and
outcomes with medical O3 gas therapy are shown in Table 2. The
patients received a number of zoledronic acid infusions ranging
from 10 to 18. At the time of ONJ diagnosis no patient presented
risk factors such as diabetes or the use of corticosteroids.
Twenty-four patients (mean age 62.5, range 41–80, 12 female)
with bone metastases due to breast (11), prostate (4)and lung
(4)cancers, myeloma (2), or osteoporosis (3), and with ONJ lesions
42.5 cm previously treated with zoledronic acid, were enroled in
the study.
No patient underwent to preventive dental screening before
starting BPs infusions. All patients received various cycles of antibioticTable 2
Patients’ demographics, baseline disease characteristics and outcomes with medical O
Patient Age Gender Primary cancer
or osteoporosis
ONJ lesion
size gradinga
Time (days) from
diagnosis of ONJ
to ﬁrst O3 gas
insufﬂations
Num
insuf
1 73 M Prostate 4A 1080 Three
interr
2 53 M Lung 4A 240 10
3 70 F Breast 4A 540 7
4 74 F Breast 4A 30 4
5 41 M Osteoporosis 4A 840 ONJ relapse in
area 44–48 after
surgery
38 on
6 64 M Prostate 4B 510 17 ap
interr
7 65 M Myeloma 4A 30 9
8d 60 M Prostate 4A 90 12 bo
to be
9 64 M Myeloma 4B 570 17
10 49 F Breast 4A 390 ONJ relapse
after partial
resection of the left
maxillary not
responsive to
antibiotics
16
11 79 M Lung 4B 270 15þ1
sx an
12 80 F Breast 4B 720 Two a
interr
13 67 F Breast 4B 420 10þ9
and d
14 66 F Osteoporosis 4A 120 One a
interr
15 79 M Breast 4A 420 9
16 51 F Breast 4B 300 15 ap
interr
17 47 F Breast 4A 90 Six ap
interr
18 63 M Lung 4A 44 6
19 77 M Prostate 4A 82 10
20 60 F Osteoporosis 4B 476 16
21 58 F Breast 4B 360 15
22 43 M Lung 4A 286 8
23 62 F Breast 4B 375 9
24 55 F Breast 4A 266 10
NB¼Necrotic bone.
a Classiﬁcation according to Weitzman et al. Ref. [43]:lesion size measured as the
b The patients who received more than 10 insufﬂations of O3 medical gas had mu
antibiotic prophylaxis.
c ODP oncological disease progression.
d The patient received two more insufﬂations of O3 medical gas while he was waitherapies after diagnosis of ONJ until the initiation of O3 treatment
without any clinical or radiological evidence of ONJ healing. Two
patients underwent hyperbaric oxygen therapy without ONJ healing.
At the time of this investigation, no patient reported sponta-
neous ONJ healing. Three patients (number 5, 10 and 14)
presented with relapsing ONJ after surgical therapy performed
to cure ONJ in other hospitals (Table 2).
ONJ was diagnosed by an experienced maxillofacial dentist on the
basis of the following criteria: presence of exposed bone in the
maxillofacial region with no evidence of healing after six weeks of
appropriate dental care [10]and in some cases of CT evaluation.
According to Weitzman classiﬁcation [43] 15 patients had a
single ONJ lesion (4A) and 9 patients had multiple lesions (4B) or
a ‘‘multifocal’’ lesion (Table 2).3 gas therapy.
ber of O3 gas
ﬂationsb
Clinical outcomes
applications than
uption
Dropped-outstop of O3 therapy due to ODP
c.
Surgery to remove NB after sequestrum. No ONJ relapse.
NB sequestrumþspontaneous expulsionþ
re-epithelisation. No ONJ relapse.
NB sequestrumþspontaneous expulsionþ
re-epithelisation. No ONJ relapse.
single lesion Surgery to remove NB after sequestrum. No ONJ relapse.
plications than
uption
Dropped-out, stop of O3 therapy due to ODP.
NB sequestrumþspontaneous expulsionþ
re-epithelisation. No ONJ relapse.
ne sequestrum ready
removed surgically
No surgical removal of NB because of ODP.
Surgery to remove NB after sequestrum. No ONJ relapse.
Surgery to remove NB after sequestrum.
No ONJ relapse after O3 gas applications.
2 multiple lesions on
d dx sites
NB sequestrum and spontaneous expulsionþmucosal
re-epithelisation at all sites. No ONJ relapse nor
decubitus after denture placement in the inferior arch.
pplications than
uption
Dropped-out stop of O3 therapy due to ODP.
multiple lesions on sx
x sites.
Surgery to remove NB after sequestrum.
No ONJ relapse.
pplication than
uption.
Dropped-out. Stop of therapy for fear of adverse effects.
NB sequestrum and spontaneous partial expulsionþ
re-epithelisation. Stop of therapy for ODP.
plications than
uption.
dropped-out stop of therapy for ODP.
plications than
uption.
Dropped-out stop of O3 therapy due to ODP.
NB sequestrumþspontaneous expulsionþ
re-epithelisation. No ONJ relapse.
Surgery to remove NB after sequestrum. No ONJ relapse.
Surgery to remove NB after sequestrum. No ONJ relapse.
Surgery to remove NB after sequestrum No ONJ relapse.
Surgery to remove NB after sequestrum. No ONJ relapse.
Surgery to remove NB after sequestrum. No ONJ relapse.
Surgery to remove NB after sequestrum. No ONJ relapse.
largest diameter 4A¼single lesion42 cm; 4B multiple lesions, largest42 cm.
ltiple lesions or single lesion but copious purulent discarge even if treated with
ting for the surgery.
Fig. 2. ONJ before starting ﬁrst O3 gas insufﬂation, necrotic area produced after 10 insufﬂations and during surgery for the removal of the necrotic bone sequestrum area (patient
no. 19): (A) ONJ lesion before the ﬁrst O3 gas insufﬂations, (B) X-ray before the ﬁrst O3 gas insufﬂations, (C) necrotic area post O3 gas insufﬂations, (D) X-ray post insufﬂations and
(E) Surgical removal of necrotic bone with periosteum dissector (no need to use devices to cut bone walls).
C.I. Ripamonti et al. / Journal of Bone Oncology 1 (2012) 81–87 85Six patients interrupted the treatment with O3 gas application for
disease progression (ﬁve patients) and for fear of an experimental
therapy (one patient). The drop-outs were considered as failure in
the Intention to treat (ITT) analysis, and excluded, in the per-protocol
(PP) analysis.
No patients reported adverse events during O3 insufﬂations
and the days after; moreover no objective or subjective symptoms
of intolerance to the O3 gas applications were observed.
In 10 patients with the largest and deeper ONJ lesions, O3 gas
therapy produced the sequestrum of the necrotic bone. Nine
patients required more than ten O3 gas applications due to multiple
lesions and/or abundant purulent secretion notwithstanding the
concomitant antibiotic therapy. In all these patients surgery was
necessary to remove the necrotic bone after sequestrum. Of inter-
est, surgical removal was possible without the resection of healthy
mandible edge because of the presence of bone sequestrum. One
patient (number 8) received two further insufﬂations while waiting
for the surgery because he had bone sequestrum ready to be
removed surgically; however because of sudden disease progres-
sion and Performance Status worsening, he was not operated on.
Fig. 2 shows the ONJ lesion before starting O3 gas insufﬂations
(picture A), the X-ray before the ﬁrst therapy with O3 (it is
possible to see the extent of necrotic lesion and the involvement
of the loop of the mandibular nerve) (B), and the necrotic area
post 10 gas insufﬂations, with the perfect soft tissue tropism,
cannot be evaluated in the picture and the mobility of the
necrotic area, easily detectable clinically (C).
The perfect condition of the soft tissues allows an extremely
conservative treatment, with a perfect mucoperiosteal seal, once
the necrotic bone has been removed. This is possible due to the
paradoxical effect of ozone, which, being an oxidant, in the cell
membranes of complex organisms, triggers a reparatory phase
that leads to the healing of mucous tissues that had been over-
turned by the damage caused by the presence of necrotic tissue
and the consequent bacterial and fungal superinfections produced
in the lesion site.
Fig. 2 also shows the post-insufﬂation X-ray (D), where the
complete demarcation of the area of necrotic bone and its
particular nearness to the emergence of the mandibular nerve
can be observed. In this case, the nerve is not at all involved in
removal and the patient will not suffer any loss of sensitivity or
paraesthesia. The photograph of removal of the necrotic fragment(E) in the operating theatre can also be seen. After the elevation
of the mucoperiosteal, vestibular and lingual ﬂaps, the necrotic
fragment can be more easily removed using a periosteal elevator,
without having to use tools for cutting bone walls. This allows
special softness during the procedure, without causing any
surgical traumas to the bone treated with bisphosphonates.
During the surgical phase, it is easy to lift the mucoperiosteal
tissue, which is completely healthy and free of ﬁbrosis and with
excellent cleavage planes, contrary to what one would expect of
an area that for months has harboured infections associated with
purulent serous secretion (the paradoxical repair effect generated
by ozone).
Six patients had complete sequestrum or partial (one patient)
spontaneous expulsion of the necrotic bone with oral mucosa re-
epithelisation, after 4 to 27 insufﬂations of O3 gas.
Fig. 3 shows the patient number 3 before starting O3 gas
insufﬂations, the necrotic bone removed by a pinch and re-
epithelizated area after the O3 gas therapy. In the area 47 (A), it
is possible to observe the infectious inﬂammatory damage to the
soft tissues, despite the fact that the necrotic lesion is slightly
inﬁltrating just below the mucosal margin. Picture (C) shows the
mobile necrotic bone removed without anaesthesia during the
seventh application, simply using an anatomical forceps in an
outpatient setting. Insufﬂation treatment was performed as usual
after removal. Picture (D) shows area 34 immediately after the
removal of the necrotic bone in an outpatient setting. It is worth
noting that the mucosal surface is completely different from the
condition in regard with both colour and continuity. The area
does not present any signs of bleeding as experienced in other
cases, the mucous membrane has formed again between the
healthy bone and the necrotic area, leading to the expulsion of
the sequestrum.
No ONJ relapse was observed in any of the 18 patients treated
with O3 gas 7 surgery, during a mean of follow-up of 18 months
(range 1–3 years). After completion of the treatment, all patients
were able to eat normally and prothesic dentures were adapted
and re-positioned for those patients who had dentures. The
patients restarted the therapy only if their Performance Karnosfsky
Status was 470; the dental team visited them every 6 months.
All together, the response rate was 75% (95% CI, 53.3–90.2%) in
the ITT analysis, and 100% (95% CI, 81.5–100%) in the per-protocol
(PP) analysis.
Fig. 3. ONJ before starting ﬁrst O3 gas insufﬂation, necrotic bone expulsed with the help of a pinch and re-epithelization (patient no. 3): (A) initial lesion (area 47), (B) post
avulsion necrotic area (position 34), inﬂammatory processes inﬁltrating the mucosae, (C) ambulatory mobile necrotic bone removal without anestesia at the seventh
application exclusively with an anatomic forcep; usual insufﬂation treatment has been followed after the drawing, (D) area 34 immediately after the ambulatory removal
of the necrotic bone, (E) X-ray shows the poorly outlined necrotic area around the alveolus of 36 after the avulsion, and (F) X-ray shows a necrotic area in position 34.
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Unfortunately it was not possible to perfom a RCT comparing
medical ozone gas therapy in respect to standard therapy because
all our 24 patients had been previously treated with various
cycles of antibiotic therapies before we could start the therapy
with O3 gas. Moreover the patients needed to wait for a long time
(Table 2) the approval of Ministry of Health in using medical O3
gas with the new indication for the treatment of patients with
ONJ related to bisphosphonate treatments.
With the data on the role of preventive measure in reducing
the risk of ONJ in patients treated with BPs [1–7,14,44–46]and the
efﬁcacy and tolerability of ozone gas [51–53]and medical O3 oil in
treating small ONJ lesions [47], we have another therapeutical
option for treating ONJ lesions when they are 42.5 cm.
Our study shows that the topical insufﬂation of ozone medical
gas on ONJ lesion 42.5 cm is able to produce a sequestrum of the
necrotic bone with 1. its spontaneous or not traumatic explusion
and the healing of the gum mucosa followed by re-epithelization
2. or surgical removal of the necrotic bone and healing of the gum
mucosa. This is an effective and original method, in the absence of
observable toxicity. Thus medical O3 gas insufﬂations appears to
be an effective and safe treatment for patients treated with BPs
who developed ONJ lesions 42.5 cm.
Three are the most important results of our study and the
result produced:1. Six patients reached the sequestrum and had a spontaneous
expulsion of the necrotic bone in respect to the 10/10 patients
with ONJr2.5 cm and treated with topical application of an
oil suspension enriched with medical O3 gas [47],2. when surgical removal of the necrotic bone after sequestrum
was necessary, the surgical resection of healthy mandible edge
was not necessary because of the presence of the sequestrum,3. no ONJ relapse appeared in our patients visited every six months
and after a mean follow -up of 18 months (range 1–3 years).
Curiously, two patients with osteoporosis who completed the
trial, requested the highest number of O3 gas insufﬂations and
this fact needs further investigation.
In conclusion, the preliminary results of this study demon-
strate that medical O3 delivered as topical gas insufﬂation can beconsidered a promising, effective, safe and simple therapeutic
option for the treatment of ONJ lesions42.5 cm. Emerging promising therapeutic options such as O3 gas
investigated in this study indicate that ONJ can be treated,
allowing patients to recover and heal from this debilitating
condition. These results add to the evidence that cancer patients and
clinicians should weigh considerable beneﬁts of BPs toward
management of skeletal health as opposed to the possible
risks posed by ONJ, an uncommon condition that may be
prevented and managed. These results should be considered as preliminary and further
investigations in a larger sample trial are required to validate
ﬁndings.Acknowledgements
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